Gallbladder Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, China, India - Size and Forecast 2024-2028

Gallbladder Cancer Therapeutics Market 2024-2028

The global gallbladder cancer therapeutics market size is estimated to grow by USD 141.47 million at a CAGR of 6.63% between 2023 and 2028. 

The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The market is dominated by using chemotherapy drugs, including gemcitabine, cisplatin, 5-FU, capecitabine, and oxaliplatin. Despite the therapeutic efficacy of these drugs, they are also associated with potential side effects. Moreover, the lack of disease-modifying drugs is another prominent unmet need for the treatment of gallbladder cancer. To overcome this challenge, various market players are conducting heavy research on developing novel therapies such as biologics with mechanisms of action such as PD-1 inhibitors. Thus, such factors are expected to drive the market in focus during the forecast period.

Technavio has segmented the market into Type, Application, and Geography 

• The type segment includes combination therapy and monotherapy
• The application segment includes hospitals, academic and medical centers, and others
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the size of the Gallbladder Cancer Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Gallbladder Cancer Therapeutics Market Segmentation by Type, Application, and Geography Analysis

Type Analysis 

Combination therapy

The market share growth by the combination therapy segment will be significant during the forecast period. Combination therapy involves the use of two or more chemotherapy drugs to achieve a synergistic clinical outcome. This segment offers various combination therapies, among which gemcitabine and cisplatin therapy is the most commonly used treatment regimen. The use of combination therapy depends on the stage of cancer; since most gallbladder cancer cases are diagnosed at an advanced stage, it necessitates the use of combination therapy along with radiation therapy after cholecystectomy. 

Get a glance at the market contribution of various segments Download PDF Sample

The combination therapy segment was valued at USD 170.25 million in 2018. The cost of combination therapies is high. However, the treatment using combination therapy requires less frequent dosing and shorter durations when compared with monotherapy. This leads to a decreased financial burden on patients and increases patient adherence to these drugs. However, these drugs are associated with more side effects than monotherapy, which poses a challenge to market growth. The increasing advances in immunotherapy research are expected to help overcome the challenges associated with side effects. Owing to these factors, the combination therapy segment of the market is expected to witness an accelerating growth momentum during the forecast period.

Application Analysis

Hospitals

Hospitals play a vital role in gallbladder cancer therapeutics by providing a range of medical services, including diagnosis, surgery, chemotherapy, and supportive care. Hospitals also contribute to research, clinical trials, and the implementation of innovative therapies, contributing significantly to advancements in gallbladder cancer treatment. The growth of hospitals in the global gallbladder cancer therapeutics market is influenced by factors such as increasing incidence of gallbladder cancer, advancements in medical technologies, and a growing emphasis on early diagnosis and treatment. Additionally, the expansion of specialized oncology departments within hospitals further contributes to the overall growth of gallbladder cancer treatment options, thus propelling the hospitals segment growth in the market during the forecast period.

Academic and medical centers

The growth of academic and medical centers in the global gallbladder cancer therapeutics market involves advancements in research, innovative treatments, and collaborative efforts. These centers play a key role in developing new therapies, conducting clinical trials, and educating professionals to improve patient outcomes.  Furthermore, the combined efforts of academic and medical centers contribute significantly to the growth and improvement of the academic and medical centers segment for gallbladder cancer therapeutics, hence contributing to the growth of the market in focus during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2023, North America accounted for the highest share of the global gallbladder cancer therapeutics market, primarily due to the high sales of approved therapeutics and the increased R&D practices undertaken by major players in the market. Moreover, factors such as the increasing awareness about the disease and the growing need for treating it in its early stages are contributing to the market growth. Furthermore, the presence of advanced healthcare infrastructure in the region and the availability of various patient assistance programs are expected to contribute to market growth. Also, the increased focus of key vendors on investing in R&D activities to maintain their market position is anticipated to have a positive impact on the market during the forecast period. 

Buy Full Report Now

Key Gallbladder Cancer Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 17 market companies, including:

AbbVie Inc.: The company offers gallbladder cancer therapeutics such as ABBV-706 which is an antibody-drug conjugate treatment.

• AstraZeneca Plc
• B.Braun SE
• Boston Scientific Corp.
• Bristol Myers Squibb Co.
• Conmed Corp.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• Medtronic Plc
• Merck KGaA
• Novartis AG
• Olympus Corp.
• Pfizer Inc.
• Sanofi SA
• Smith and Nephew plc
• Sun Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Gallbladder Cancer Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Gallbladder Cancer Therapeutics Market Drivers

The strong incidence of gallbladder cancer in developing countries is the key factor driving market growth. The global gallbladder cancer therapeutics market is currently witnessing a rise in the incidence rate of gallbladder cancer in various developing countries of the world. Furthermore, India, Japan, South Korea, and Central/Eastern Europe, including the Czech Republic, Slovakia, and Slovenia, have also reported a higher incidence rate of the disease when compared with the global incidence rate in the same year.

Moreover, the high incidence of gallbladder cancer in these countries can be attributed to the predisposition to carcinogenesis. The genetic predisposition to carcinogenesis originated from the population migration patterns in the Himalayas and Central Asia through the Bering Strait in the past few decades. The strong incidence of gallbladder cancer in these countries has further led to a rise in the patient population, which, in turn, will induce the demand for gallbladder cancer therapeutics and drive the market growth during the forecast period.

Significant Gallbladder Cancer Therapeutics Market Trends

The rising adoption of immunotherapy is the primary trend shaping market growth. Immunotherapy is a cancer treatment that helps strengthen the immune system's ability to find and attack cancer cells. Immunotherapy is being adopted to treat gallbladder cancers that cannot be removed by surgery. Some gallbladder tumors have specific mutations in their DNA, which are more favorably treated by immunotherapy drugs. Two types of immunotherapy, Keytruda (pembrolizumab), and Opdivo (nivolumab), are approved to treat gallbladder tumors with a certain genetic marker called MSI.

Moreover, another immunotherapy called Durvalumab, a type of PD-L1 inhibitor, is under study, which includes a combination of Durvalumab with chemotherapy in previously untreated patients whose cancer is locally advanced, recurrent, or has spread to other parts of the body. Therefore, the presence of such immunotherapy drugs will increase their adoption, thus stimulating the global gallbladder cancer therapeutics market during the forecast period.

Major Gallbladder Cancer Therapeutics Market Challenges

Lack of adequate healthcare infrastructure in developing nations is a challenge that affects market growth. Radiotherapy and chemotherapy devices require ample installation space due to their large size. In underdeveloped and emerging economies such as India and Argentina and in South American and African countries, there is a lack of adequate healthcare infrastructure due to limited healthcare expenditure. This is one of the major factors restraining the adoption of cancer treatment in countries such as India, Brazil, and South Africa.

In addition, the World Health Organization (WHO) recommends at least one teletherapy unit per million population. As per this recommendation, the minimum required number of teletherapy units in India is around 1,250 units as against the presently available 545 units, marking a considerable shortfall of nearly 700 units. Moreover, the high treatment cost associated with cancer led to low adoption of this treatment in developing countries. Thus, such factors are major challenges to the market and will impede the market growth during the forecast period.

Buy Now Full Report

Key Gallbladder Cancer Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Gallbladder Cancer Therapeutics Market Customer Landscape

Segment Overview

The gallbladder cancer therapeutics market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028. 

• Type Outlook
  • Combination therapy
  • Monotherapy

• Application Outlook
  • Hospitals
  • Academic and medical centers
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • South America
    • Chile
    • Brazil 
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Gallbladder Cancer Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the gallbladder cancer therapeutics market between 2024 and 2028
• Precise estimation of the gallbladder cancer therapeutics market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of gallbladder cancer therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch